#4 - Merck & Co. (NYSE:MRK)
Merck & Co. Inc. (NYSE: MRK) is another inflation-fighting stock in the pharmaceutical sector. The bullish narrative with Merck centers around its oncology portfolio and its flagship drug, Keytruda, which continues to be approved for earlier-stage cancers and is experiencing robust global demand from metastatic indications.
However, Keytruda is only one drug in the company’s extensive oncology portfolio, which is supposed to grow from $10 billion in 2023 to over $20 billion by 2030.
Beyond oncology, Merck has a solid track record of developing innovative medicines covering vaccines, infectious diseases, immunology, and other unmet medical needs. The company has a proven track record of bringing drugs to market while being able to produce solid returns for shareholders. One element of those returns is a dividend that yields over 3.3%, has an average annual growth rate of around 5%, and has been increasing for 14 consecutive years.
About Merck & Co., Inc.
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
More about Merck & Co., Inc.- Current Price
- $81.48
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 12 Buy Ratings, 11 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $117.12 (43.7% Upside)
